Keywords: Tekmira Pharma, Marina Biotech, Licensing deal, RNAi thereapeutics

Tekmira and Marina Biotech in license agreement for novel RNAi technology

Article | 30 November 2012

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals (Nasdaq: TKMR) has obtained a worldwide, non-exclusive license to a novel RNAi ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Marina Biotech

Tekmira Pharmaceuticals

Go to company listing